Gutiérrez-Cota F, Avendaño-Reyes JM, González-Altamirano J, Marín-Fragoso ME, Aceves A, Campos E, García-Flores E, Flores-Rendón ÁR, Jaramillo-Ramírez HJ

Language: Spanish
References: 12
Page: 20-25
PDF size: 183.62 Kb.

ABSTRACT

Background: Non alcoholic steatohepatitis (NASH) is an entity with morphologic changes very similar to Alcoholic Steatohepatitis, and sometimes these pathological abnormalties can’t be distinguished exclusively by histological bases. Progression to cirrhosis is slow and variable with increased risk of liver failure and hepatocellular carcinoma.
Materials and methods: This is a transversal, observational, multicentric, non-randomized trial aimed to study the hepatic findings in the morbidly obese patient who undergoes bariatric surgery. Liver biopsy was performed to all patients who had bariatric surgery in 3 Hospitals in Mexicali, Baja California. The sample was treated with hematoxylin and eosin stains, Masson’s trichrome stain, Perls' Prussian blue stain and Periodic Acid Schiff stain for the evaluation of histological changes and fibrosis. A Kleiner and Brunt Schema modified was used as Histological Scoring System for grading and staging NAFLD.
Results: 54 patients were included, 47% were classified as “NAFLD definitely for steatohepatitis”, 52% for “NAFLD definitely non-steatohepatitis” and the rest (2%) didn’t present steatosis. Of the 25 cases with NAFLD with steatohepatitis, 4 were staged as E0, 11 staged as E1a and E1b, and 10 were staged as E3. Of the 28 cases with NAFLD without steatohepatitis, 18 didn’t show fibrosis (E0) and 5 of them were classified as E1, 3 of them as E2, one as E3 and one as E4.
Conclusions: Non alcoholic fatty liver disease is a very common entity in the group of morbidly obese patients (98%) we studied. There is a high prevalence of Non Alcoholic Steatohepatitis and hepatic fibrosis among the group of study (47%).

REFERENCES

1. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, y col. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca: Instituto Nacional de Salud Pública, 2006.

2. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725.

3. Sheth, SG, Gordon, FD, Chopra, S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137.

4. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3.

5. John BD. Surgical treatment for obesity and its impact on non alcoholic steatohepatitis. Clin Liver dis 2007;11:141-154.

6. Janus O, Zobair Y. Epidemiology and Natural History of NAFLD and NASH. Clin Liver Dis 2007;11:1-16.

7. Shivakumar C, Geoffrey CF, Etsuko H, Toshiji S, George KK, José DS and the Asia–Pacific Working Party on NAFLD. Nonalcoholic fatty liver disease in the Asia–Pacific region: Definitions and overview of proposed guidelines. J Gastroenterol and Hepatol 2007;22:778-787.

8. Weston SR, Leydon W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005;41:372- 379.

9. Lerman I, Aguilar-Salinas CA, Gómez-Pérez FJ, Reza A, Hernández S, Vázquez C, Rull JA. Rev Endocrinologia y Nutrición 2004; 12(4) Supl. 3.

10. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005;41:372.

11. Patton HM, Sirlin C, Behling C, et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006;43:413.

12. Mathew MY, et al. Nonalcoholic Fatty LIver Disease. Romil Saxena. Practical Hepatic Pathology. A Diagnostic Approach 2011;435-440.